Publication:

Distinct Recognition of Complement iC3b by Integrins αXβ2 and αMβ2

Loading...
Thumbnail Image

Open/View Files

Date

2017-03-14

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Proceedings of the National Academy of Sciences
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Xu, Shutong, Wang, Jianchuan, Wang, Jia-Huai, and Springer, Timothy A. 2017. Distinct Recognition of Complement IC3b by Integrins αXβ2 and αMβ2. Proceedings of the National Academy of Sciences of the United States of America 114, no. 13: 3403-408.

Abstract

Recognition by the leukocyte integrins αXβ2 and αMβ2 of complement iC3b-opsonized targets is essential for effector functions including phagocytosis. The integrin-binding sites on iC3b remain incompletely characterized. Here, we describe negative-stain electron microscopy and biochemical studies of αXβ2 and αMβ2 in complex with iC3b. Despite high homology, the two integrins bind iC3b at multiple distinct sites. αXβ2 uses the αX αI domain to bind iC3b on its C3c moiety at one of two sites: a major site at the interface between macroglobulin (MG) 3 and MG4 domains, and a less frequently used site near the C345C domain. In contrast, αMβ2 uses its αI domain to bind iC3b at the thioester domain and simultaneously interacts through a region near the αM β-propeller and β2 βI domain with a region of the C3c moiety near the C345C domain. Remarkably, there is no overlap between the primary binding site of αXβ2 and the binding site of αMβ2 on iC3b. Distinctive binding sites on iC3b by integrins αXβ2 and αMβ2 may be biologically beneficial for leukocytes to more efficiently capture opsonized pathogens and to avoid subversion by pathogen factors.

Description

Other Available Sources

Research Data

Keywords

Multidisciplinary

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories